Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Seung Kak | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Kim, Jeong Han | - |
dc.contributor.author | Lee, Chan Uk | - |
dc.contributor.author | Yeon, Jong Eun | - |
dc.contributor.author | Suh, Sang Jun | - |
dc.contributor.author | Jung, Young Kul | - |
dc.contributor.author | Kim, Yun Soo | - |
dc.contributor.author | Kim, Ju Hyun | - |
dc.contributor.author | Kwon, Oh Sang | - |
dc.date.accessioned | 2021-11-20T23:40:51Z | - |
dc.date.available | 2021-11-20T23:40:51Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-05 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/128171 | - |
dc.description.abstract | Background/Aims: The clinical significance of partial virological response (PVR) in patients undergoing antiviral therapy is not well known. This study investigated whether PVR after 2 years of entecavir (ETV) therapy is associated with hepatocellular carcinoma (HCC) development in cirrhotic patients. Methods: A total of 472 naive patients with hepatitis B virus (HBV)-associated cirrhosis who were treated with ETV for at least 2 years were retrospectively enrolled. Clinical characteristics, laboratory data, PVR, and noninvasive fibrosis markers (aspartate aminotransferase to platelet ratio and FIB-4 index) at 2 years after ETV commencement were analyzed for HCC risk. Results: After excluding those who developed HCC within 2 years of ETV therapy, 359 patients (mean age, 51 +/- 10 years; male 64.3%) were examined. During a median follow-up of 82 months, 80 patients developed HCC. In the univariate analysis, older age (hazard ratio [HR], 1.056; p<0.001), PVR (HR, 2.536; p=0.002), higher aspartate aminotransferase (HR, 1.018; p=0.005), lower albumin level (HR, 0.463; p<0.001), lower platelet count (HR, 0.993; p=0.01), and higher FIB-4 index (HR, 1.141; p<0.001) at 2 years after ETV commencement were risk factors for HCC. In the multivariate analysis, older age (HR, 1.046; 95% confidence interval [CI], 1.022 to 1.072; p<0.001), PVR (HR, 2.358; 95% CI, 1.310 to 4.245; p=0.004), and higher FIB-4 index (HR, 1.103; 95% CI, 1.035 to 1.177; p=0.003) were independent risk factors. Conclusions: PVR and higher FIB-4 index after 2 years of ETV therapy were independent risk factors for HCC. Therefore, efforts to accomplish a complete virological response and reduce the FIB-4 index should be made. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | EDITORIAL OFFICE GUT & LIVER | - |
dc.subject | PLATELET RATIO INDEX | - |
dc.subject | ASPARTATE-AMINOTRANSFERASE | - |
dc.subject | LIVER FIBROSIS | - |
dc.subject | FIB-4 | - |
dc.subject | DNA | - |
dc.title | Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jung, Young Kul | - |
dc.identifier.doi | 10.5009/gnl20074 | - |
dc.identifier.scopusid | 2-s2.0-85106540690 | - |
dc.identifier.wosid | 000652440500013 | - |
dc.identifier.bibliographicCitation | GUT AND LIVER, v.15, no.3, pp.430 - 439 | - |
dc.relation.isPartOf | GUT AND LIVER | - |
dc.citation.title | GUT AND LIVER | - |
dc.citation.volume | 15 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 430 | - |
dc.citation.endPage | 439 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002716890 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | PLATELET RATIO INDEX | - |
dc.subject.keywordPlus | ASPARTATE-AMINOTRANSFERASE | - |
dc.subject.keywordPlus | LIVER FIBROSIS | - |
dc.subject.keywordPlus | FIB-4 | - |
dc.subject.keywordPlus | DNA | - |
dc.subject.keywordAuthor | Partial virological response | - |
dc.subject.keywordAuthor | Entecavir | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Hepatitis B virus | - |
dc.subject.keywordAuthor | Liver cirrhosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.